To identify antigens of Brucella spp. that are potentially involved in stimulating a protective T-cell-mediated immune response, previous studies identified 10 clones from a Brucella abortus 2308 genomic library with primed lymphocytes as probes. One selected positive clone (182) contained an insert of 1.2 kb which was identified, sequenced and characterised. The deduced amino acid sequence of the open reading frame (ORF) revealed 82% and 81% identity to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) enzymes from Agrobacterium tumefaciens and Xanthobacter flavus, respectively. Southern blot analysis demonstrated that the gap gene is present in only one copy in the Brucella genome. B. abortus GAPDH was then expressed in Escherichia coli as a fusion protein with the maltose-binding protein (MBP). To demonstrate the functional activity of Brucella GAPDH, E. coli gap mutants were transformed with a Brucella pMAL-gap construct. Genetic complementation was achieved and as a result E. coli mutants were able to grow on glucose or other carbon source medium. The humoral and cellular immune responses to the recombinant (r) GAPDH were characterised. In Western blots, sera from naturally infected cattle and sheep showed antibody reactivity against rGAPDH. In response to in-vitro stimulation by rGAPDH, splenocytes from mice vaccinated with rGAPDH or B. abortus S19 were able to produce ª-interferon and tumour necrosis factor-AE but not interleukin (IL)-4. Furthermore, gap associated with murine IL-12 gene in a DNA vaccine formulation partially protected mice against experimental infection.
Introduction
Brucella abortus is a facultative intracellular bacterium that infects man and domestic animals [1] . The pathological manifestations of brucellosis are diverse and include arthritis, endocarditis and meningitis in man, whereas bovine brucellosis is characterised by spontaneous abortion [2] . Pathogenic intracellular bacteria survive within a host cell by several mechanisms, circumventing a potent immune response [3] . Moreover, little is known about the cellular and molecular mechanisms used by B. abortus to penetrate and resist destruction within host cells. Several lines of evidence suggest that cell-mediated immunity can limit the pathogenesis of brucellosis [4] [5] [6] . Studies in this laboratory have demonstrated that the induction of a Th1-type of immune response with production of ª-interferon (IFN-ª) and generation of cytotoxic CD8 þ T cells appear to play a pivotal role in protection against B. abortus infection [7, 8] . Brucella proteins that induce an appropriate immune response are most likely responsible for generating host protection. Therefore, identifying these bacterial proteins would be critical for understanding the immune response to B. abortus infection and vaccination.
Several Brucella genes have been cloned, and the proteins that they encode have been characterised [9] [10] [11] [12] [13] . However, little is understood regarding the importance of these bacterial proteins in the immune response. Only few specific Brucella proteins such as L7/L12 ribosomal protein [14] , peptides comprising certain epitopes of Cu/Zn superoxide dismutase [15] and P39 (a periplasmic binding protein) combined with CpG motifs [16] were able to engender partial protection based on T-cell responses. Therefore, a greater understanding of the relationship between Brucella proteins and host protection is required. Thus, the identification of individual bacterial proteins that trigger T lymphocytes is crucial to define how the immune system functions in this disease.
In an attempt to identify new B. abortus proteins capable of stimulating T cells, a B. abortus genomic library was screened with bovine lymphocytes from animals primed to the living bacterium [17] . The bacterial proteins from 10 clones of the 300 examined were recognised by primed lymphocytes. One of these clones, termed 182, was analysed in this study. DNA sequence analysis of clone 182 revealed the existence of an open reading frame (ORF) containing the whole sequence of B. abortus gap gene encoding the glyceraldehyde-3-phosphate-dehydrogenase enzyme (GAPDH). Interestingly, the GAPDH protein homologue has been associated with pathogenesis in other infectious disease models and has been shown to be a putative vaccine candidate against Schistosoma japonicum and S. mansoni infections [18, 19] . In the present study, the heterologous complementation of Escherichia coli gap mutant strains by Brucella GAPDH biological activity, was examined, and purified GAPDH recombinant (r) protein was produced for molecular and immunological characterisation. Furthermore, the study examined the recognition of rGAPDH protein by antibodies and Th1 cells from infected animals and the protection induced when it was administered as a DNA vaccine associated with IL-12 gene.
Materials and methods

Bacterial strains and growth conditions
The bacterial strains used in this study are listed in Table 1 . E. coli DH5AE strain was grown at 378C on Luria-Bertani medium [22] . All E. coli mutants (DS111, DS112 and DS 113) and DS 110 were grown at 378C on M63 medium supplemented with casamino acids 0.1%, 0.12 mM tryptophane, 0.17 mM methionine, 34 mM succinate and glycerol 0.88% or, in complementation studies, with 10 mM glucose and 10 mM maltose. Isopropyl-â-D-thiogalactoside (IPTG) was used at a final concentration of 25 mM in complementation experiments. B. abortus strains were grown in Brucella Broth (BB) (Difco Laboratories, Detroit, MI, USA). The antibiotic concentrations used were as follows: ampicillin 100 mg=L, erythromycin 200 mg=L and chloramphenicol 25 mg=L.
DNA procedures
DNA manipulation (i.e., preparation, digestion and ligation of plasmid DNA) and gel electrophoresis were performed by standard procedures [22] .
DNA and amino acid sequence analysis
A 1.2-kb clone was obtained by screening a B. abortus 2308 genomic library with bovine lymphocytes from primed animals as probes [17] . Double-stranded DNA sequences of the 1.2-kb fragment inserted into the pBluescript II SK À phagemid was performed by the dideoxy-chain termination method [23] , with an Automated Laser Fluorescence DNA sequencer from Amersham Pharmacia Biotech (Piscataway, NJ, USA). The clone was sequenced with the Thermo Sequenase kit and the primers used were M13 reverse or M13 universal sequence from AmershamPharmacia Biotech. The sequence data were compiled and analysed with the sequence analysis program DNASIS V5.00 (Hitachi Software). Subsequent homology searches were performed with the BLAST programs available from the National Biotechnology Information Center [24] . Amino acid sequences were aligned with the ClustalW Service from the European Bioinformatics Institute available on the internet [http://www2.ebi.ac.uk/ clustalw].
Southern blot analysis
The Brucella S19 strain was cultured for 72 h in BB. Then, 200 ìl of the bacterial suspension were harvested by centrifugation at 13 000 rpm for 5 min and the pellet was suspended in 1000 ìl of cell resuspension solution (10 mM Tris-HCl, pH 7.0, 10 mM EDTA, pH 8.0, 300 mM NaCl) and centrifuged. The pellet was resuspended in 300 ìl of cell lysis solution (25 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0, 10 mM NaCl), 300 ìl of lysozyme (10 mg=ml) were added and incubated at 658C for 20 min. The lysed cell suspension was treated once with an equal volume of phenolchloroform (v/v) and centrifuged. Then, 0.6 ml of chloroform was added to the aqueous phase recovered from the mixture and centrifuged again. Finally, the DNA was precipitated on 2.5 volumes of ice-cold ethanol (99.5%) plus 10 ìl of 5 M NaCl. The pellet was dissolved in 50 ìl of TE buffer (10 mM Tris-HCl, pH 7.2, 1 mM EDTA) and treated with RNAase 10 ìg=ml at 378C for 15 min. The concentration of DNA was measured spectrophotometrically at 260 nm. For DNA hybridisation, 10 ìg of genomic DNA were digested with ClaI, EcoRI or HindIII. The resulting fragments were separated by agarose 1% gel electrophoresis, passively transferred on to a nylon membrane (Hybond-N; AmershamPharmacia Biotech) and UV-cross-linked. The EcoRI-HindIII fragment corresponding to the coding region of the gap gene was used as a DNA probe. This fragment was labelled with [AE-32 P] dCTP by random priming (Gibco BRL). The hybridisation was performed under stringent conditions (388C, formamide 50%) as described previously [22] . The nylon membrane was subjected to autoradiography for 18 h at À808C.
Subcloning and expression of Brucella gap gene in E. coli
The B. abortus gap gene was amplified by PCR from the 1.2-kb genomic clone and subcloned into the expression vector pMAL-c2 (New England Biolabs, Beverly, MA, USA). In this vector, the cloned foreign gene was expressed as a fusion protein with maltosebinding protein (MBP) at the amino terminus so that the recombinant protein could be purified by affinity chromatography with an amylose resin. Primers, containing one artificial restriction site at each end, were constructed according to the gap nucleotide sequence. The primers sequences were (forward) 59-GGGGAATT CATGGCAGTTCGCGTCGCA-39 (EcoRI) and (reverse) 59-CGCAAGCTTTCAGATCAGCTTGCCCAA-39 (HindIII). PCR was performed with a 10-ìl volume containing assay buffer (200 mM Tris-HCl, pH 8.4, 500 mM KCl, 500 mM MgCl 2 ), a mixture of the four deoxynucleoside triphosphates at 10 mM each, a 5 pmoles= ìl concentration of each primer, 10 ng of template DNA and 2.5 U of Taq DNA polymerase (Promega). Amplification was performed with a PTC-100 TM Programmable Thermal Controller (M J Research) at 958C for 3 min followed by 30 cycles of denaturation for 30 s at 958C, annealing for 45 s at 588C and extension for 1 min at 728C. The amplified gene fragment was digested with appropriate restriction endonucleases and cloned into pMAL-c2. The recombinant plasmid (pMAL-gap) was used to transform E. coli DH5AE, and single recombinant colonies were selected. Plasmid DNA was extracted with Wizard Plus SV Minipreps (Promega) and digested with EcoRI and HindIII to verify the presence of the insert. The recombinant protein was expressed and purified as described previously [25] . The expression of the fusion protein resulted in the formation of the inclusion bodies that were solubilised by washing the bacterial pellet twice with wash buffer containing urea (0.1 M Tris-HCl, pH 8.8, and 5 M urea) and twice with water. To avoid degradation of the fusion protein, the following protease inhibitors were added during the extraction procedure: 10 mM EDTA, 2 mM PMSF, 1 ìM Pepstatin and 10 ìM E-64. The protein concentration was determined by the Bradford assay [26] with bovine serum albumin as a standard.
Molecular modelling
The amino acid sequence of GAPDH (target sequence) from B. abortus was submitted to theoretical molecular modeling by the SWISS-MODEL computer program (Automated Protein Modeling Server) [27] . Initially, a search was made for GAPDH sequences of known three-dimensional structure and a pair-wise alignment was performed with the target sequence. Thermotoga maritima and Bacillus stearothermophilus presented 55.4% and 57.4% sequence identity with B. abortus GAPDH protein, respectively. This level of sequence identity is sufficient to infer a homologous relationship and, therefore, a similar three-dimensional structure that permits the construction of a molecular model by homology-modelling techniques. The model was assessed with the computer program RasMol [28] .
Complementation assay
To verify the functional activity of the B. abortus GAPDH, E. coli mutants for gapA (˜gapA), gapB (˜gapB), or gapA/B (˜gapA/B) genes were transformed with 0.5 ìg of the pMAL-gap plasmid. To check the functional complementation, the transformed cells were selected by their ability to grow on glucose or other carbon source medium supplemented with the appropriate antibiotics.
SDS-PAGE and immunoblotting
E. coli extracts expressing the MBP-GAPDH fusion protein, and purified MBP-GAPDH protein were separated on a denaturing polyacrylamide 10% gel by electrophoresis [29] . From the gel, the proteins were transferred to nitrocellulose membranes (BioRad) by Western blot as described previously [30] . The nitrocellulose membranes were blocked with skim milk 5% at 48C overnight, and treated with rabbit anti-MBP serum (1 in 10 000) or sera from naturally Brucellainfected cattle (1 in 1000) or sheep (1 in 50) for 2 h at room temperature. After reaction with the primary antibody, the blots were washed three times with TBST (0.5 M NaCl-0.02 M Tris, pH 7.5, Tween 20 0.05%) and incubated for 1 h at room temperature with anti-rabbit IgG-alkaline phosphatase conjugate (1 in 10 000) (Promega), rabbit anti-bovine IgG-peroxidase conjugate (1 in 10 000) (Sigma) or rabbit anti-sheep IgG-peroxidase conjugate (1 in 2000) (Southern Biotechnology). After three washes with TBST, the reaction was developed after incubation at room temperature with NBT (nitroblue tetrazolium chloride) and BCIP (5-bromo-4-chloro-3-indolyl-1-phosphate) for alkaline phosphatase or DAB (3,3-diaminobenzidine tetrahydrochloride) (Gibco BRL) for peroxidase conjugated-antibody.
Cytokine assay
Spleens of mice vaccinated with rGAPDH or B. abortus strain S19 were passed through steel mesh to obtain single-cell suspensions. Splenocytes were then isolated by density gradient centrifugation with Ficoll (Sigma 
DNA vaccine construction and preparation
The B. abortus gap gene was amplified by PCR and subcloned into the mammalian expression vector pCMV-link (a gift from Dr J. Ulmer from Chiron). This experiment was performed with the same set of primers containing an artificial restriction site at each end (EcoRI-HindIII) and with the same protocol as described above for cloning the gap gene into pMAL-c2. The pCMV-gap plasmid was sequenced to confirm the presence and orientation of the gap gene. The mouse IL-12-encoding plasmid pCI-IL-12 was kindly provided by Dr J. S. Harms (University of Wisconsin-Madison, USA). The pCI-IL-12 plasmid was designed with a linker to fuse p35 cDNA with p40 cDNA to produce a single-chain IL-12 protein, ensuring not only that p35 and p40 were expressed equally, but also that no free p40 subunit interfered with IL-12 activity [31] . Both plasmids were prepared with a Wizard Maxiprep DNA purification kit (Promega, Madison, WI, USA) as described in the manufacturer's protocol.
Immunisation protocol
BALB/c mice, average 8 weeks old, were divided into five groups of eight mice each. For intramuscular DNA immunisation, mice were pre-injected with 10 mM cardiotoxin (Sigma) as described previously [32] . At weeks 0, 2, 4 and 6, 100 ìg of pCMV-link (a gift from Dr J. Ulmer from Chiron), pCMV-gap, or pCMV-gap plus pCI-IL-12 constructs were administered intramuscularly into mouse quadriceps. As control groups, mice were immunised with 5 3 10 4 cfu of B. abortus strain 19 or PBS alone.
B. abortus challenge
Two weeks after the last immunisation, mice were challenged with 1 3 10 5 cfu of B. abortus strain 2308. Animals were then killed 2 weeks after challenge. Spleens from individual animals were homogenised in PBS, 10-fold serially diluted and plated on Brucella Broth Agar (Difco). Plates were incubated at 378C in air with CO 2 5% and the number of cfu was counted visually after 3 days.
Statistical analysis
Statistical analyses were performed with Student's t test in a computer software package (MINITAB; Minitab Inc., State College, PA, USA).
Nucleotide sequence accession no.
The nucleotide sequence presented in this study has been deposited in the GenBank under accession no. AF095338.
Results
Clone 182 containing the gap gene from B. abortus
One complete open reading frame of 1008 bp was identified in a 1213-bp clone. The nucleotide (nt) and amino acid (aa) sequences of Brucella gap gene are shown in Fig. 1 . The coding region was translated with the computer program DNASIS v 5.0. The Brucella gap gene encodes a polypeptide of 336 aa with a predicted molecular mass of 37 kDa. The putative active site of the enzyme is located between aa 151 and 157. This ORF was subjected to protein and nucleic acid homology searches by the Basic Local Alignment Search Tool (BLAST) service at the National Center for Biotechnology Information (NCBI). This revealed that the ORF encoding the Brucella GAPDH aa sequence has 48%, 81% and 82% identity with the GAPDH encoded by gap genes of E. coli, Xanthobacter flavus and Agrobacterium tumefaciens, respectively. The alignment of the Brucella GAPDH aa sequence with those of other micro-organisms showed the highest degree of identity with the GAPDH from A. tumefaciens, which is closer phylogenetically to the genus Brucella (Fig. 2) .
gap gene copy number
The gap gene appears to be a single copy gene in the Brucella genome. Southern blotting of the genomic DNA with a fragment comprising the gap ORF as probe showed a single band in lanes 3 and 4 that contained DNA digested with EcoRI or HindIII (both enzymes do not cut within the coding region of GAPDH) and two bands in lane 2 that has DNA digested with ClaI (this enzyme has one site within the coding region of GAPDH) ( Fig. 3 ).
Brucella GAPDH three-dimensional structure
The model constructed for B. abortus GAPDH showed that this molecule adopts the same three-dimensional topology as GAPDH of other micro-organisms. This structure consists of 260 H-bridges, 14 AE-helices, 24 âsheets and 37 loops (Fig. 4) . This model suggests a glycolytic function for Brucella GAPDH similar to other bacterial GAPDH, based upon its tertiary structure. The enzyme active site, composed of alanine, serine, cysteine, threonine, threonine, asparagine and cysteine residues, is shown in ball-and-stick format.
Functional complementation of E. coli mutants by B. abortus gap gene
To determine whether the gap gene sequence of B. abortus encodes a functional GAPDH, complementation of three E. coli mutants was tested. The plasmid pMAL-gap, containing all translational signals thought to be necessary for expression of Brucella GAPDH protein, was used to transform E. coli gap mutants unable to grow on glucose minimal medium. As shown in Table 2 , growth of E. coli strains DS110 and DS111 was not affected in the presence of glucose or maltose. In contrast, no growth was detected when E. coli mutants DS112 and DS113 were used. However, after complementation, DS112 and DS113 mutant strains harbouring the pMAL-gap plasmid grew in the presence of glucose or maltose, indicating functional activity as a glycolytic enzyme of the GAPDH from B. abortus.
Recognition of Brucella rGAPDH by sera of infected animals
The heterologous expression of Brucella GAPDH protein was performed in E. coli as an MBP fusion. Recombinant GAPDH was purified by affinity chromatography on an amylose resin column as demonstrated previously [25] . The E. coli extract carrying the pMAL-gap construct and the purified rGAPDH were analysed by immunoblotting with rabbit antiserum to MBP and sera from naturally infected cattle and sheep (Fig. 5) . The observed molecular mass of the recombinant protein was in agreement with the estimated molecular mass of the MBP fusion, 79 kDa (37 kDa for GAPDH and 42 kDa for MBP). The immunoblotting analysis confirmed the identity of the MBP-GAPDH fusion protein produced by rabbit anti-MBP antibody recognition. Lastly, this result demonstrated that IgG antibodies to rGAPDH were detected in sera of naturally infected cattle and sheep. The detection of total IgG specific for rGAPDH in sera of these animals is relevant because they are the natural hosts for Brucella infection.
Induction of a Th1-type of immune response by rGAPDH immunisation
To further examine T-cell reactivity to Brucella rGAPDH, the cytokine profile of mice immunised with rGAPDH or B. abortus S19 was determined. Fig. 6 shows that high levels of IFN-ª and TNF-AE were detected in cell supernates of both groups of mice that had been stimulated in vitro with rGAPDH. Animals immunised with rGAPDH showed a slight increase in the production of IL-4 compared with mice vaccinated with strain S19; however, this was not statistically significant. As negative control, MBP alone was used to stimulate splenocytes, and no significant T-cell activation was detected in either mouse group (data not shown). In contrast, ConA significantly stimulated cytokine production by splenocytes from both vaccinated mouse groups (data not shown). Nevertheless, groups immunised with both rGAPDH and strain S19 demonstrated a polarised Th1-type of immune response. Furthermore, these results confirmed that T cells from mice vaccinated with strain S19 could recognise rGAPDH, as previously shown when lymphocytes from primed cattle were used as probes to screen a Brucella genomic library [17] .
Protection efficacy of gap DNA immunisation
Two weeks after the last DNA immunisation, mice were challenged with 1 3 10 5 cfu of B. abortus strain 2308. The protective immunity was determined 2 weeks after infection by determining the number of B. abortus cfu in the spleen. gap gene alone engendered no protection against challenge with a B. abortus virulent strain, whereas gap associated with murine IL-12 gene as adjuvant induced partial protection against infection (Table 3 ).
Discussion
The search for new vaccines against Brucella spp., overcoming the drawbacks of current live attenuated vaccines, is a goal of several laboratories world-wide. Efforts have been made to isolate, identify and characterise new bacterial antigens. However, only moderate protection has been induced by these subunit vaccines [14] [15] [16] . One of the more promising candidates was identified in this laboratory, the Brucella L7/ L12 ribosomal protein, a T-cell immunodominant antigen [14] . Taking a different approach, a genomic library of B. abortus 2308 was screened for expressed antigens that reacted with T lymphocytes from cattle vaccinated with B. abortus S19 [17] . Clone 182 was one of 10 positive clones isolated from the library. The deduced aa sequence of the ORF from clone 182 demonstrated homology to GAPDH of different bacterial species, mainly with GAPDH of A. tumefaciens, where 82% sequence identity was found. Furthermore, a molecular model to predict the three-dimensional structure of Brucella GAPDH was performed, and its topology consisting of 260 H-bridges, 14 AE-helices, 24 â-sheets and 37 loops was very similar to tertiary structure of the GAPDH from other bacteria. However, to determine the biological activity of Brucella GAPDH E. coli gap A (DS112), gap B (DS111) or the null (DS113) mutant (which are unable to grow on glucose minimal medium) were complemented with the pMAL-gap construct. E. coli mutant strains DS112 and DS113 complemented with the pMAL-gap plasmid grew in the presence of glucose or maltose, demonstrating the biological function of the GAPDH from B. abortus as a glycolytic enzyme.
GAPDH is a glycolytic enzyme; however, a number of other physiological functions have been associated with this molecule -such as assembly of microtubules [33] , adhesion to fibronectin, myosin and actin [34] , and the ability to serve as a receptor for plasmin [35] . Interestingly, immunological studies of anti-S. mansoni responses in individuals from endemic areas identified GAPDH (Sm37) as a vaccine candidate based on the correlation of antibody titres induced against this antigen and resistance to re-infection [36] . Also, GAPDH has been involved as an important immunogenic molecule in several infectious disease models such as African trypanosomiasis, candidiasis, Lyme disease and Chagas' diseases [37] [38] [39] [40] .
This study analysed both the humoral and the cellmediated immune responses induced by Brucella rGAPDH. Immunoblotting analysis revealed that IgG antibodies from naturally infected cattle and sheep recognised Brucella rGAPDH. The detection of specific antibodies to rGAPDH in sera from these hosts is relevant for several reasons. First, cattle and sheep are important natural hosts for Brucella infection [1] . Second, levels of IgG in infected hosts are correlated with the presence of active infection [41] . Third, protective antibodies in the mouse model appear to be predominantly of the IgG isotype [42] . However, because of the intracellular nature of Brucella infection, the induction of a cellular immune response is critical for effective host clearance of the bacterium. Therefore, IL-4, IFN-ª and TNF-AE levels were measured in splenocyte supernates of mice vaccinated with rGAPDH or B. abortus S19. The results clearly indicated that rGAPDH induced a Th1-type of immune response in mice, although the levels of IFN-ª and TNF-AE in the rGAPDH-immunised group were lower than in the group vaccinated with strain S19. A similar observation was reported by our group and others when a Brucella recombinant protein was used as antigen, and the less potent T-cell activation stimulus is probably due to the antigenic complexity of B. abortus S19 compared with a single molecule [43] . Immunisation of mice with strain S19 induces protective immunity and splenocytes from such mice produce high levels of IFN-ª. This fact is consistent with the hypothesis that a protective immune response to Brucella infection requires the production of proinflammatory cytokines such as IFN-ª and TNF-AE [44] .
As GAPDH is a conserved protein, at least in the functionally constrained domains of the molecule, the Brucella GAPDH aa sequence was analysed with a TEPITOPE algorithm which predicts HLA-DR ligands within the repeated GAPDH motifs [45] . Comparison analysis of Brucella GAPDH aa sequence with human, mouse and cattle GAPDH indicated that this protein shares only 42%, 42% and 44% identity, respectively. TEPITOPE prediction revealed that the promiscuous Tcell epitopes are on aa positions 7-20, 70-80, 195-213 and 306-325 of Brucella GAPDH and, therefore, they are not overlapping the region of the molecule homologous to human, mouse or cattle GAPDH (data not shown). Furthermore, it was demonstrated that nonprimed T cells from human, mouse or cattle were not activated following in-vitro stimulation with rGAPDH (data not shown). Similar findings were observed by Pitarch and co-workers with sera from healthy subjects to Candida albicans GAPDH [40] . Therefore, vaccination experiments with Brucella GAPDH would probably not induce cross-reactive recognition by human or animal T cells, thus avoiding autoimmune reactions.
Gene vaccines have been employed successfully in animal studies to induce protective immunity against a variety of bacteria, viruses and parasites [46] . This type of vaccine is capable of eliciting a strong cell-mediated immunity that is required to control infection by many intracellular agents [47] . Moreover, endogenous expression of antigen from DNA introduced into host cells leads to processed peptides presented with the major histocompatibility complex class I, able to induce cytotoxic T lymphocytes [48] . As CD8 þ T cells seems to be the major T-cell subset involved in controlling Brucella infection [8] , the gap gene was used in a DNA vaccine formulation to protect mice against experimental infection. The gap gene delivered intramuscularly induced no protection in BALB/c mice, whereas administration of pCMV-gap plus pCI-IL-12 engendered moderate protection against challenge. This synergic effect of IL-12 of gap DNA immunisation could be related to direct activation of CD8 þ T cells or enhanced type I cytokine production, or both [49] .
The results presented here demonstrate the involvement of rGAPDH in the immune response to B. abortus. rGAPDH was shown to be immunoreactive, inducing both humoral and cellular immune responses in natural hosts and mice during the course of infection. T-cell activation following rGAPDH in-vitro stimulation, measured here by IFN-ª and TNF-AE, confirmed the T-cell reactivity of this molecule as originally observed from the genomic library [17] . Furthermore, DNA immunisation with gap gene plus murine IL-12expressing plasmid DNA induced partial protection against Brucella infection. 
